All In Biotech

Drug Trial Radar · NCT06072612

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

404

Planned (sponsor's estimate)

Start

Dec 5, 2023

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Conditions

  • Breast Cancer
  • Metastatic Breast Cancer
  • Breast Neoplasm
  • Breast Cancer Metastatic
  • End Stage Cancer

Interventions

  • SV-BR-1-GMBiological

    SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity

  • CyclophosphamideDrug

    Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.

  • Interferon infiltration of the inoculation siteDrug

    Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.

  • RetifanlimabDrug

    Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.

  • Treatment of Physician's ChoiceDrug

    Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to 60 months

Locations

79 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic-Comprehensive Cancer Center-Breast Clinic

    Phoenix, Arizona · Recruiting

  • University of Arizona-Cancer Center

    Tucson, Arizona · Recruiting

  • Los Angeles cancer Network_Anaheim

    Anaheim, California · Recruiting

  • Comprehensive Blood and Cancer Center

    Bakersfield, California · Recruiting

  • Cedars-Sinai Cancer Beverly Hills

    Beverly Hills, California · Recruiting

  • Los Angeles Cancer Network_Corona

    Corona, California · Recruiting

  • Los Angeles cancer Network_Fountain Vallley

    Fountain Valley, California · Recruiting

  • Los Angeles Cancer Network_Glendale

    Glendale, California · Recruiting

  • Hoag Hospital Center

    Irvine, California · Recruiting

  • Hoag Hospital Irvine

    Irvine, California · Recruiting

  • Los Angeles Cancer Network

    Los Angeles, California · Recruiting

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Facility

    Los Angeles, California · Recruiting

  • Los Angeles Cancer Network_Century City

    Los Angeles, California · Recruiting

  • UCLA-Hematology/Oncology Medical Plaza

    Los Angeles, California · Recruiting

  • UCLA-Hematology/Oncology_LA 2

    Los Angeles, California · Recruiting

  • UCLA-Hematology/Oncology_LA

    Los Angeles, California · Recruiting

  • Los Angeles Cancer Network_Pasadena

    Pasadena, California · Recruiting

  • Los Angeles cancer Network_Riverside

    Riverside, California · Recruiting

  • UC San Diego

    San Diego, California · Recruiting

  • St. John's Cancer Center

    Santa Monica, California · Recruiting

  • UCLA-Department of Medicine Hematology/Oncology-Parkside

    Santa Monica, California · Recruiting

  • UCLA-Hetamtology/Oncology_S Monica

    Santa Monica, California · Recruiting

  • Torrance Memorial Cancer Center

    Torrance, California · Recruiting

  • Los Angeles Cancer Network_Valley Pres

    Van Nuys, California · Recruiting

  • Cedars-Sinai Breast Health Services Building

    West Hollywood, California · Recruiting

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut · Recruiting

  • University of Miami _SCCC - Aventura

    Aventura, Florida · Recruiting

  • University of Miami-SCCC-Lennar

    Coral Gables, Florida · Recruiting

  • University of Miami_SCCC-Coral Springs

    Coral Springs, Florida · Recruiting

  • University of Miami Hospital and Clinics - Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • University of Miami_SCCC-Hollywood

    Hollywood, Florida · Recruiting

  • Mayo Clinic Florida-Comprehensive Cancer Center

    Jacksonville, Florida · Recruiting

  • University Of Miami-SCCC-Miami

    Miami, Florida · Recruiting

  • University of Miami_SCCC - Kendall

    Miami, Florida · Recruiting

  • Advent Health - Orlando

    Orlando, Florida · Recruiting

  • University of Miami-SCCC-Plantation

    Plantation, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Southern Illinois University-Simmons

    Springfield, Illinois · Recruiting

  • Carle Foundation Cancer Institute-Urbana

    Urbana, Illinois · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.